Carl Zeiss Meditec Delays Executive Pay Vote Amid Financial Strain

Zeiss Meditec withdraws executive pay vote and suspends annual forecast as EBITA plunges 77%. Stock near 52-week low, with China headwinds and new outlook due in 2026.

In a last-minute move ahead of its annual general meeting, the supervisory board of Carl Zeiss Meditec has pulled a key agenda item. The proposal concerning executive compensation has been withdrawn. According to the company, the remuneration system requires a comprehensive review and will not be put to a shareholder vote again until 2027.

Share Price and Forecast Reflect Mounting Pressure

The decision comes during a period of significant challenges for the medical technology firm. Carl Zeiss Meditec's stock price has fallen approximately 65% over the past year, trading close to its 52-week low. This decline mirrors broader operational difficulties.

Previously issued guidance for the fiscal year has been provisionally suspended. The company had initially projected revenue of around €2.3 billion and an EBITA margin of 12.5%. Management has indicated that a revised forecast, alongside details on planned cost-reduction initiatives and a reprioritization of R&D activities, will be provided no later than May 12, 2026, with the release of half-year results.

Quarterly Performance Highlights Operational Challenges

The company's recent financial performance underscores the rationale behind the board's cautious steps. For the first quarter of the current fiscal year, Carl Zeiss Meditec reported a sharp decline in its operating result. EBITA plummeted to €8.1 million, down dramatically from €35.2 million in the prior-year period. Concurrently, revenue contracted to €467.0 million from €490.5 million.

Management cites a confluence of factors weighing on business performance. Geopolitical uncertainties, coupled with restrained capital investment in key markets like the United States and China, are creating headwinds. Additional regulatory changes are further complicating the operating environment.

Structural Headwinds in China Pose Sustained Risk

A particular area of concern is the company's business in China. The market for intraocular lenses is facing substantial pressure due to the implementation of volume-based procurement tenders. This system, alongside intensifying competition from local manufacturers, threatens significant price erosion. Carl Zeiss Meditec acknowledges that this constitutes a structural issue unlikely to be resolved in the short term.

With the executive pay vote shelved and annual guidance withdrawn, investors are left with an incomplete picture of the company's near-term trajectory. The stock is expected to remain under pressure until more concrete updates are provided in 2026.